BETA BUGS LIMITED

Their core work

Beta Bugs Limited is a UK-based insect biotechnology company specialising in the selective breeding and genetic characterisation of high-performance insect strains for commercial applications. Their core product is a proprietary platform — the Platform for Typing of Insect Strains — which allows systematic identification, selection, and development of insect breeds with superior traits, likely targeting yield, feed conversion, or pathogen resistance relevant to the insect protein industry. They progressed from feasibility research (PLATYPIS, 2019) to full commercialisation (CHiPInB, 2020–2022), indicating a company that has moved from R&D into market deployment. Their work sits at the intersection of applied entomology, selective breeding, and agri-food innovation.

What they specialise in

How they've shifted over time

Beta Bugs entered H2020 in 2019 with PLATYPIS, a small EUR 50,000 SME Phase 1 feasibility study — a signal they were testing market readiness and validating the business case for their insect strain typing platform. Within a year they secured CHiPInB, a EUR 688,230 SME Phase 2 commercialisation grant, indicating the feasibility work was successful and the company pivoted sharply from research validation to full market deployment. There is no meaningful early-versus-late keyword divergence because both projects are the same technology at different maturity levels — the real evolution is from concept to product.

Beta Bugs is on a clear commercialisation trajectory — having completed the classic SME Instrument Phase 1 → Phase 2 pathway, they are likely building out their insect breed product and seeking industry customers rather than pursuing further R&D grants.

How they like to work

Beta Bugs has acted as sole coordinator on both projects, which is characteristic of the SME Instrument scheme — designed for individual companies to develop their own innovations rather than build consortia. No consortium partners are recorded, meaning their EU project experience has been entirely self-directed rather than collaborative. Any future collaboration would therefore be with an organisation new to their network, and they should be approached as a technology owner seeking partners to access distribution, markets, or complementary science — not as an experienced consortium operator.

Beta Bugs has no recorded consortium partners from their H2020 participation, as both grants were awarded under the SME Instrument scheme which supports single-company projects. Their network, if any, exists outside the formal EU project structure.

What sets them apart

Beta Bugs appears to be one of a very small number of companies in Europe focused specifically on the genetics and systematic typing of insect strains rather than just insect farming or processing — a foundational layer of the insect protein supply chain that most competitors in the sector do not address. If their platform can characterise and certify insect breed performance, they occupy a niche analogous to seed genetics in conventional agriculture, which is a highly defensible position. For any consortium working on insect-based food, feed, or waste processing, they would bring rare and specific IP rather than general entomological knowledge.

Highlights from their portfolio

• CHiPInB
  At EUR 688,230, this SME Phase 2 commercialisation grant is the company's main project and confirms that the European Commission validated both the technology and the business case for their insect breed typing platform.
• PLATYPIS
  This EUR 50,000 SME Phase 1 study is notable as the proof-of-concept that directly unlocked the larger CHiPInB grant — demonstrating a textbook SME Instrument funding pathway executed in under two years.